Reoto Takei

Dr. Reoto Takei

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Respirology
Verified
Journal Article
Closed access
RTReoto Takei
Reoto Takei
KBKevin K. Brown
Kevin K. Brown
YYYasuhiko Yamano
Yasuhiko Yamano
KKKensuke Kataoka
Kensuke Kataoka
TYToshiki Yokoyama
Toshiki Yokoyama
YKYasuhiro Kondoh
Yasuhiro Kondoh

19 September 2017 in Respirology
Verified
Journal Article
Closed access
PDF file
RTReoto Takei
Reoto Takei
MAMachiko Arita
Machiko Arita
SKShogo Kumagai
Shogo Kumagai
YIYuhei Ito
Yuhei Ito
FTFumiaki Tokioka
Fumiaki Tokioka
TITadashi Ishida
Tadashi Ishida

20 April 2017 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
RTReoto Takei
Reoto Takei
MAMachiko Arita
Machiko Arita
SKShogo Kumagai
Shogo Kumagai
YIYuhei Ito
Yuhei Ito
MNMaki Noyama
Maki Noyama
TITadashi Ishida
Tadashi Ishida
Chronic fibrosing idiopathic interstitial pneumonia (CFIIP) has a potential risk of acute exacerbation (AE). However, the usefulness of cellular analysis of bronchoalveolar lavage fluid (BALF) has never been evaluated. This study aimed to evaluate the impact of the lymphocyte differential count > 15% in BALF on the mortality of patients with AE of CFIIP. We retrospectively analysed 37 patients with AE of CFIIP who underwent BAL on admission. Patients were divided into two groups: one group consisting of those with a lymphocyte differential count > 15% and the other consisting of those with a lymphocyte differential count ≤ 15%. We compared the 90-day mortality between the two groups as the primary outcome, using the two-tailed log-rank test. The median follow-up duration was 6.9 months. Twenty-four patients had a lymphocyte differential count > 15%. The 90-day mortality was significantly higher in the group with a lymphocyte differential count ≤ 15% than in the group with a lymphocyte differential count > 15% (long rank test, p = 0.003). In the multivariate analysis a lymphocyte differential count > 15% was shown to be an independent favourable prognostic factor for 90-day mortality (HR: 0.125; 95% CI: 0.0247–0.589; p = 0.009). A lymphocyte differential count > 15% in BALF may be associated with favourable outcomes in patients with AE of CFIIP.

22 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
YMYoshikazu Mutoh
Yoshikazu Mutoh
TUTakumi Umemura
Takumi Umemura
TNTakeshi Nishikawa
Takeshi Nishikawa
KKKaho Kondo
Kaho Kondo
YNYuta Nishina
Yuta Nishina
YKYasuhiro Kondoh
Yasuhiro Kondoh
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.

1 December 2018 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
RTReoto Takei
Reoto Takei
MAMachiko Arita
Machiko Arita
FTFumiaki Tokioka
Fumiaki Tokioka
HTHiromasa Tachibana
Hiromasa Tachibana
HTHironobu Tokumasu
Hironobu Tokumasu
TITadashi Ishida
Tadashi Ishida
Background: We have sometimes observed interstitial pneumonia which had chronic course and unknown causes but not diagnosed as idiopathic pulmonary fibrosis (IPF). However, the treatment strategy was not established definitely. To clarify the usefulness of cyclosporin A (CsA) in idiopathic chronic fibrosing interstitial pneumonia (iCFIP) without IPF, we examined longitudinal changes in pulmonary physiology. Methods: Japanese patients with iCFIP without IPF treated with CsA were identified retrospectively. Linear mixed-effects models were used to evaluate changes in pulmonary physiology after adjusting for age, sex, and smoking history. Primary outcomes were longitudinal trajectories of the percent predicted forced vital capacity (%FVC), percent predicted diffusing capacity for carbon monoxide (%DLco), and composite physiologic index (CPI) before and after CsA. Results: Thirty-three patients were included. Before CsA initiation, %FVC, %DLco, and CPI declined at rates of 9.1%, 8.6% and −7.1 per 1 year, respectively. After CsA initiation, the gradient of %FVC showed significant improvements in 0–1 years (6.2%±3.0%; P<0.01) and in 1–2 years (10.0%±3.6%; P<0.01); %DLco improved in 0–1 year (4.0%±4.6%; P=0.09) and in 1–2 years (7.0%±5.6%; P=0.02); and CPI improved in 0–1 year (3.2%±3.3%; P=0.06) and in 1–2 years (4.6%±4.1%; P=0.03). Conclusions: CsA for iCFIP without IPF may be associated with improvements in pulmonary physiology in 2 years. Further studies are needed to determine the role of CsA in iCFIP without IPF.

25 April 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
HKHirofumi Kamata
Hirofumi Kamata
KTKazufumi Takamatsu
Kazufumi Takamatsu
KFKoichi Fukunaga
Koichi Fukunaga
SCShotaro Chubachi
Shotaro Chubachi
KNKensuke Nakagawara
Kensuke Nakagawara
AYAkihito Yokoyama
Akihito Yokoyama